Vor Biopharma Q4 2023 GAAP EPS $(0.39) Beats $(0.51) Estimate
Portfolio Pulse from Benzinga Newsdesk
Vor Biopharma (NASDAQ:VOR) reported a Q4 2023 GAAP EPS of $(0.39), surpassing the analyst consensus estimate of $(0.51) by 23.53%.
March 20, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vor Biopharma reported a Q4 2023 GAAP EPS of $(0.39), exceeding the consensus estimate of $(0.51) by 23.53%.
Beating earnings estimates typically leads to positive investor sentiment and can result in a short-term increase in stock price. The significant beat of 23.53% suggests that Vor Biopharma is performing better than expected, which could lead to increased investor confidence and demand for VOR shares.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100